Nicotinamide does not influence cytokines or exhaled NO in human experimental endotoxaemia

Clinical and Experimental Immunology

Volumn 135, Issue 1, 2004, Pages 114-118

  Soop, A ^a   Albert, J ^b   Weitzberg, E ^a   Bengtsson, A ^c   Nilsson, C G ^d   Sollevi, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Institute of Surgical Sciences ^*

Author keywords

Cytokines; Human; Nicotinamide; Nitric oxide; Sepsis

Indexed keywords

CYTOKINE; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; NICOTINAMIDE; NITRIC OXIDE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; ENDOTOXEMIA; HEART RATE; HEMODYNAMIC MONITORING; HUMAN; INFUSION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 0347319059     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02315.x     Document Type: Article

References (34)

1. American College of Chest Physicians/Society of Critical Care Medicine. Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-74.
2. Murphy K, Haudek SB, Thompson M, Giroir BP. Molecular biology of septic shock. New Horiz 1998; 6:181-93.
3. Brandtzaeg P, Mollnes TE, Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 1989; 160:58-65.
4. Fiorentino DF, Zlotnik A, Mosmann TR et al. 1L-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147:3815-22.
5. van Deuren M. Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections. Eur J Clin Microbiol Infect Dis 1994; 13:S12-6.
6. Bone RC, Grodzin CJ, Balk RA. Sepsis, a new hypothesis for pathogenesis of the disease process. Chest 1997; 112:235-43.
7. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990; 87:10043-7.
8. Palmer RM, Bridge L, Foxwell NA, Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br J Pharmacol 1992; 105:11-2.
9. American Thoracic Society. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999 Am J Respir Crit Care Med 1999; 160:2104-17.
10. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993; 6:1368-70.
11. Herulf M, Svenungsson B, Lagergren A et al. Increased nitric oxide in infective gastroenteritis. J Infect Dis 1999; 180:542-5.
12. Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Intragastric nitric oxide production in humans: measurements in expelled air. Gut 1994; 35:1543-6.
13. Adrie C, Monchi M, Dinh-Xuan AT et al. Exhaled and nasal nitric oxide as a marker of pneumonia in ventilated patients. Am J Respir Crit Care Med 2001; 163:1143-9.
14. Soop A, Sollevi A, Weitzberg E, Lundberg JON, Palm J, Albert J. Exhaled NO and plasma cGMP increase after endotoxin infusion in healthy volunteers. Eur Respir J 2003; 21:594-9.
15. Pellat-Deceunynck C, Wietzerbin J, Drapier JC. Nicotinamide inhibits nitric oxide synthase mRNA induction in activated macrophages. Biochem J 1994; 297:53-8.
16. Burkart V, Koike T, Brenner HH, Kolb H. Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro. Diabetologia 1992; 35:1028-34.
17. Hiromatsu Y, Sato M, Tanaka K, Ishisaka N, Kamachi J, Nonaka K. Inhibitory effects of nicotinamide on intercellular adhesion molecule-1 expression on cultured human thyroid cells. Immunology 1993; 80:330-2.
18. Pero RW, Axelsson B, Siemann D et al. Newly discovered anti-inflammatory properties of the benzamides and nicotinamides. Mol Cell Biochem 1999; 193:119-25.
19. Zingarelli B, Salzman AL, Szabo C. Protective effects of nicotinamide against nitric oxide-mediated delayed vascular failure in endotoxic shock: potential involvement of polyADP ribosyl synthetase. Shock 1996; 5:258-64.
20. Szabo C, Dawson VL. Role of poly (ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 1998; 19:287-98.
21. Partrick DA, Moore FA, Moore EE et al. Neutrophil priming and activation in the pathogenesis of postinjury multiple organ failure. New Horiz 1996; 4:194-210.
22. Horsman MR, Hoyer M, Honess DJ et al. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol 1993; 27:131-9.
23. Suffredini AF, Hochstein HD, McMahon FG. Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999; 179:1278-82.
24. Ayoub IA, Lee EJ, Ogilvy CS et al. Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. Neurosci Lett 1999; 259:21-4.
25. Fukuzawa M, Satoh J, Muto G et al. Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol Lett 1997; 59:7-11.
26. Soop A, Johansson C, Hjemdahl P, Kristiansson M, Gyllenhammar H, Li N, Sollevi A. Adenosine treatment attenuates cytokine IL-6 responses to Endotoxin challenge in Healthy Volunteers. SHOCK 2003; 19:503-7.
27. Li N, Soop A, Sollevi A, Hjemdahl P. Multi-cellular activation in vivo by endotoxin in humans - limited protection by adenosine infusion. Thromb Haemost 2000; 84:381-7.
28. Andersen HU, Jorgensen KH, Egeberg J et al. Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans. Diabetes 1994; 43:770-7.
29. Liaudet L, Pacher P, Mabley JG et al. Activation of poly (ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med 2002; 165:372-7.
30. Theisen M, Trager K, Tugtekin I et al. Effects of nicotinamide, an inhibitor of PARS activity, on gut and liver O2 exchange and energy metabolism during hyperdynamic porcine endotoxemia. Intensive Care Med 2001; 27:586-92.
31. Scharte M, Nofer JR, Aken HV et al. Nicotinamide increases systemic vascular resistance in ovine endotoxemia. Intensive Care Med 2003; 29:989-94.
32. Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003; 131:48-52.
33. Knip M, Douek IF, Moore WP et al. Safety of high-dose nicotinamide: a review. Diabetologia 2000; 43:1337-45.
34. Bussink J, Stratford MR, van der Kogel AJ et al. Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. Radiother Oncol 2002; 63:285-91.